Current and investigational treatments for spinal muscular atrophy

Bibliography

• Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978;15:409-13
   PubMed Web of Science ®Google Scholar
• Feldkotter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-68
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pinto AM, Wan L, et al. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc Natl Acad Sci USA 2013;110:19348-53
   PubMed Web of Science ®Google Scholar
• DiDonato CJ, Chen XN, Noya D, et al. Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res 1997;7:339-52
   Google Scholar
• Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999;96:6307-11
   PubMed Web of Science ®Google Scholar
• Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002;30:377-84
   PubMed Web of Science ®Google Scholar
• Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000;15:228-37
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65
   PubMed Web of Science ®Google Scholar
• Kaplan JC. Gene table of monogenic neuromuscular disorders (nuclear genome only) Vol 19. No 1 January 2009. Neuromuscul Disord 2009;19:77-98
   PubMedGoogle Scholar
• Okamoto K, Saito K, Sato T, et al. [A case of spinal muscular atrophy type 0 in Japan]. No To Hattatsu 2012;44:387-91
   Google Scholar
• Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999;3:49-51
   PubMedGoogle Scholar
• Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995;52:518-23
   PubMed Web of Science ®Google Scholar
• Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996;15:3555-65
   PubMed Web of Science ®Google Scholar
• Pellizzoni L, Baccon J, Charroux B, et al. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr Biol 2001;11:1079-88
   PubMed Web of Science ®Google Scholar
• Mourelatos Z, Abel L, Yong J, et al. SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J 2001;20:5443-52
   PubMed Web of Science ®Google Scholar
• Pellizzoni L, Kataoka N, Charroux B, et al. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998;95:615-24
   PubMed Web of Science ®Google Scholar
• Yong J, Wan L, Dreyfuss G. Why do cells need an assembly machine for RNA-protein complexes? Trends Cell Biol 2004;14:226-32
   PubMedGoogle Scholar
• Rossoll W, Jablonka S, Andreassi C, et al. SMN, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003;163:801-12
   PubMed Web of Science ®Google Scholar
• Akten B, Kye MJ, Hao le T, et al. Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc Natl Acad Sci USA 2011;108:10337-42
   PubMed Web of Science ®Google Scholar
• Zhang HL, Pan F, Hong D, et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci 2003;23:6627-37
   PubMed Web of Science ®Google Scholar
• Will CL, Luhrmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol 2001;13:290-301
   PubMed Web of Science ®Google Scholar
• Durell TM, Pumariega AJ, Rothe EM, et al. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2009;21:26-37
   Google Scholar
• Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp Cell Res 2004;296:51-6
   PubMed Web of Science ®Google Scholar
• Coady TH, Lorson CL. SMN in spinal muscular atrophy and snRNP biogenesis. Wiley Interdiscip Rev RNA 2011;2:546-64
   PubMed Web of Science ®Google Scholar
• Winkler C, Eggert C, Gradl D, et al. Reduced UsnRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev 2005;19:2320-30
   PubMed Web of Science ®Google Scholar
• Gabanella F, Butchbach ME, Saieva L, et al. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One 2007;2:e921
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008;133:585-600
   PubMed Web of Science ®Google Scholar
• Baumer D, Lee S, Nicholson G, et al. Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet 2009;5:e1000773
   PubMed Web of Science ®Google Scholar
• Praveen K, Wen Y, Matera AG. A Drosophila model of spinal muscular atrophy uncouples snRNP biogenesis functions of survival motor neuron from locomotion and viability defects. Cell Rep 2012;1:624-31
   Google Scholar
• Fallini C, Bassell GJ, Rossoll W. High-efficiency transfection of cultured primary motor neurons to study protein localization, trafficking, and function. Mol Neurodegener 2010;5:17
   PubMed Web of Science ®Google Scholar
• Fallini C, Zhang H, Su Y, et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J Neurosci 2011;31:3914-25
   PubMed Web of Science ®Google Scholar
• Peter CJ, Evans M, Thayanithy V, et al. The COPI vesicle complex binds and moves with survival motor neuron within axons. Hum Mol Genet 2011;20:1701-11
   PubMed Web of Science ®Google Scholar
• Bi J, Tsai NP, Lu HY, et al. Copb1-facilitated axonal transport and translation of kappa opioid-receptor mRNA. Proc Natl Acad Sci USA 2007;104:13810-15
   Google Scholar
• de La Vega LA, Stockert RJ. The cytoplasmic coatomer protein COPI. A potential translational regulator. J Biol Chem 1999;274:31135-8
   Google Scholar
• Javaherian A, Cline HT. Coordinated motor neuron axon growth and neuromuscular synaptogenesis are promoted by CPG15 in vivo. Neuron 2005;45:505-12
   PubMed Web of Science ®Google Scholar
• Bechara E, Davidovic L, Melko M, et al. Fragile X related protein 1 isoforms differentially modulate the affinity of fragile X mental retardation protein for G-quartet RNA structure. Nucleic Acids Res 2007;35:299-306
   Google Scholar
• Sanchez G, Dury AY, Murray LM, et al. A novel function for the survival motoneuron protein as a translational regulator. Hum Mol Genet 2013;22:668-84
   Google Scholar
• Wang T, Bray SM, Warren ST. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev 2012;22:256-63
   PubMedGoogle Scholar
• Darnell JC, Richter JD. Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol 2012;4:a012344
   PubMed Web of Science ®Google Scholar
• Lunke S, El-Osta A. Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics 2013;10:677-87
   Google Scholar
• Sendtner M. Therapy development in spinal muscular atrophy. Nat Neurosci 2010;13:795-9
   PubMed Web of Science ®Google Scholar
• Azzouz M, Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004;114:1726-31
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120:1253-64
   PubMed Web of Science ®Google Scholar
• Nurputra DK, Lai PS, Harahap NI, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet 2013;77:435-63
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65
   PubMed Web of Science ®Google Scholar
• Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-4
   PubMed Web of Science ®Google Scholar
• Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004;22:346-53
   PubMed Web of Science ®Google Scholar
• Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010;2:35ra42
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011;20:681-93
   PubMed Web of Science ®Google Scholar
• Glascock JJ, Shababi M, Wetz MJ, et al. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochem Biophys Res Commun 2012;417:376-81
   PubMed Web of Science ®Google Scholar
• Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 2013;21:282-90
   PubMed Web of Science ®Google Scholar
• Coady TH, Lorson CL. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J Neurosci 2010;30:126-30
   PubMed Web of Science ®Google Scholar
• Shababi M, Glascock J, Lorson CL. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Ther 2011;22:135-44
   PubMed Web of Science ®Google Scholar
• Singh NK, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006;26:1333-46
   PubMed Web of Science ®Google Scholar
• Porensky PN, Mitrpant C, McGovern VL, et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012;21:1625-38
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011;3:72ra18
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478:123-6
   PubMed Web of Science ®Google Scholar
• Seo J, Howell MD, Singh NN, et al. Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta 2013;1832:2180-90
   PubMed Web of Science ®Google Scholar
• Kernochan LE, Russo ML, Woodling NS, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet 2005;14:1171-82
   PubMed Web of Science ®Google Scholar
• Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12:2481-9
   PubMed Web of Science ®Google Scholar
• Garbes L, Riessland M, Holker I, et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009;18:3645-58
   PubMed Web of Science ®Google Scholar
• Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003;54:647-54
   PubMed Web of Science ®Google Scholar
• Tsai LK, Tsai MS, Lin TB, et al. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 2006;24:286-95
   PubMed Web of Science ®Google Scholar
• Tsai LK, Tsai MS, Ting CH, et al. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med (Berl) 2008;86:1243-54
   PubMed Web of Science ®Google Scholar
• Arnold WD, Burghes AH. Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol 2013;74:348-62
   Google Scholar
• Dayangac-Erden D, Bora-Tatar G, Dalkara S, et al. Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics. Arch Med Sci 2011;7:230-4
   Google Scholar
• Hahnen E, Eyupoglu IY, Brichta L, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006;98:193-202
   PubMed Web of Science ®Google Scholar
• Riessland M, Ackermann B, Forster A, et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 2010;19:1492-506
   PubMed Web of Science ®Google Scholar
• Somers E, Riessland M, Schreml J, et al. Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy. Neurosci Lett 2013;544:100-4
   Google Scholar
• Mattis VB, Bowerman M, Kothary R, et al. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett 2008;442:54-8
   PubMed Web of Science ®Google Scholar
• Lorson CL, Strasswimmer J, Yao JM, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998;19:63-6
   PubMed Web of Science ®Google Scholar
• Pellizzoni L, Charroux B, Dreyfuss G. SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc Natl Acad Sci USA 1999;96:11167-72
   PubMed Web of Science ®Google Scholar
• Talbot K, Ponting CP, Theodosiou AM, et al. Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism? Hum Mol Genet 1997;6:497-500
   PubMed Web of Science ®Google Scholar
• Wang CH, Papendick BD, Bruinsma P, et al. Identification of a novel missense mutation of the SMN(T) gene in two siblings with spinal muscular atrophy. Neurogenetics 1998;1:273-6
   Google Scholar
• Carrel TL, McWhorter ML, Workman E, et al. Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J Neurosci 2006;26:11014-22
   PubMed Web of Science ®Google Scholar
• Mattis VB, Ebert AD, Fosso MY, et al. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet 2009;18:3906-13
   PubMed Web of Science ®Google Scholar
• Mattis VB, Tom Chang CW, Lorson CL. Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neurosci Lett 2012;525:72-5
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008;118:3316-30
   PubMed Web of Science ®Google Scholar
• Corti S, Nizzardo M, Nardini M, et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010;133:465-81
   PubMed Web of Science ®Google Scholar
• Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-80
   PubMed Web of Science ®Google Scholar
• Wadman RI, Bosboom WM, van der Pol WL, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev 2012;4:CD006282
   PubMed Web of Science ®Google Scholar
• Wadman RI, Bosboom WM, van der Pol WL, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev 2012;4:CD006281
   Google Scholar
• Miller RG, Moore DH, Dronsky V, et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001;191:127-31
   PubMed Web of Science ®Google Scholar
• Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 2003;18:537-41
   PubMed Web of Science ®Google Scholar
• Brichta L, Holker I, Haug K, et al. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006;59:970-5
   PubMed Web of Science ®Google Scholar
• Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010;5:e12140
   PubMed Web of Science ®Google Scholar
• Kissel JT, Scott CB, Reyna SP, et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One 2011;6:e21296
   PubMed Web of Science ®Google Scholar
• Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4:e5268
   PubMed Web of Science ®Google Scholar
• Kissel JT, Elsheikh B, King WM, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve 2014;49:187-92
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007;68:51-5
   PubMed Web of Science ®Google Scholar
• Liang WC, Yuo CY, Chang JG, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008;268:87-94
   PubMed Web of Science ®Google Scholar
• Chen TH, Chang JG, Yang YH, et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 2010;75:2190-7
   PubMed Web of Science ®Google Scholar
• Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003;60:1601-3
   PubMed Web of Science ®Google Scholar
• Seo J, Howell MD, Singh NN, et al. Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta 2013;1832:2180-90
   PubMed Web of Science ®Google Scholar
• Towne C, Schneider BL, Kieran D, et al. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 2010;17:141-6
   PubMed Web of Science ®Google Scholar
• Toromanoff A, Cherel Y, Guilbaud M, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008;16:1291-9
   Web of Science ®Google Scholar
• Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol Ther 2013;21:2148-59
   PubMed Web of Science ®Google Scholar
• Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013;20:450-9
   PubMed Web of Science ®Google Scholar
• Passini MA, Cheng SH. Prospects for the gene therapy of spinal muscular atrophy. Trends Mol Med 2011;17:259-65
   PubMed Web of Science ®Google Scholar
• Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013;19:40-50
   PubMed Web of Science ®Google Scholar
• Goulet BB, Kothary R, Parks RJ. At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Curr Mol Med 2013;13:1160-74
   PubMed Web of Science ®Google Scholar